Is Rival ATTR-CM Trial Failure and New AI Deals Altering The Investment Case For Alnylam (ALNY)?
In recent days, Alnylam Pharmaceuticals has benefited from the late-stage failure of AstraZeneca and Ionis's competing ATTR-CM trial, ...
Read the original at Yahoo Finance ↗
- Topics
- Healthcare
- Tracked via
- “AI Falures”